Pfizer retracts premature Exubera approval statement

Share this article:
Pfizer retracted a remark made by its chief executive this morning that Exubera was approved in the US. In an interview on CNBC, Hank McKinnell said that the drug gained FDA approval. Pfizer shares rose in early trading after the premature announcement. Pfizer subsequently issued a statement saying Exubera (inhaled human insulin powder) has been approved by the European Commission but has not yet been approved by the FDA. “Pfizer regrets an incorrect statement it made to CNBC about the regulatory status of Exubera in the US and is correcting it with CNBC,” the company said. The European Commission approved the drug yesterday, while the FDA user fee date is today. According to a report in The Wall Street Journal Online, McKinnell said in a follow-up interview with CNBC that Pfizer expects a decision soon, and that the earlier, incorrect statement was due to a mistake in the company’s internal communications. A Pfizer spokesperson was not immediately available for comment.
Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Media

Programmatic buying stands to disrupt healthcare marketing

Programmatic buying stands to disrupt healthcare marketing

Programmatic ad buying hasn't exactly taken over the industry, but its approach has precipitated a paradigm shift, media experts say.

Five things for pharma marketers to know: Wednesday, October 22

Five things for pharma marketers to know: ...

Novo partners with YouTube star for diabetes vids; hedge fund wants Amgen to split up; J&J ramps up Ebola vaccine production.

Mucinex gets a revamp

Mucinex gets a revamp

After 10 years of "Mucinex In. Mucus Out," the congestion-relief treatment gets a new look from Reckitt Beckinser's recently appointed AOR McCann New York.